The war against influenza: discovery and development of sialidase inhibitors.
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs--zanamivir and oseltamivir--and highlights the value of structure-based drug design in this process.
Institute for Glycomics, Gold Coast Campus, Griffith University, Queensland 4222, Australia. m.vonitzstein@griffith.edu.au
Mark
M
von Itzstein
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D053139:Oseltamivir / Q000494:pharmacology*; D053243:Zanamivir / Q000494:pharmacology*
D000998:Antiviral Agents; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir